PrIMAVeRa at ESCMID Global 2026: Bringing AMR Science to Munich

PrIMAVeRa partners joined the global infectious disease and clinical microbiology community in Munich for ESCMID Global 2026, held at Messe München from 17–21 April 2026.

Attending ESCMID Global offered PrIMAVeRa partners a valuable opportunity to present the project's progress, discuss the potential of vaccines and monoclonal antibodies (mAbs) as tools to reduce antimicrobial resistance (AMR), and connect with key stakeholders from research, clinical practice, and policy.

Dr Mariana Guedes, clinical researcher at Servicio Andaluz de Salud, presented preliminary results from the PrIMAVeRa individual participant data meta-analysis during an oral session focused on the clinical impact of drug resistance in Gram-negative infections. The analysis examined the relationship between resistance to 3rd generation cephalosporins and patient outcomes, with results suggesting that such resistance may not be associated with increased mortality in patients with Enterobacterales bloodstream infections. The presentation also highlighted the broader methodological challenges facing AMR research, including difficulties in data gathering and the persistent lack of disaggregated data.

Dr Marlieke De Kraker (University of Geneva) presenting “Data: what’s available today and where are the key gaps?”.

PrIMAVeRa's work also featured in a session titled "Accelerating access: rethinking HTA to unlock AMR solutions", chaired by Dr Charlotte Vernhes and Dr Maarten Postma. The session underscored significant data gaps that continue to limit the development of novel AMR interventions. The European Health Data Space was highlighted as a critical mechanism for developing common standards, though participants stressed that dedicated funding is needed to establish and sustain it.

Dr Marlieke De Kraker, University of Geneva, presented “Data: what’s available today and where are the key gaps?”. PrIMAVeRa's own modelling work was presented as a concrete resource for estimating the value of vaccines and mAbs in reducing AMR burden across Europe. A clear call was made to move this work beyond the research phase and apply it meaningfully in both EU and national policy contexts, rather than leaving it on the shelf.

As PrIMAVeRa approaches the final phase of its, engagements like this are an important part of ensuring that its tools and insights reach and benefit the wider community working to address the global AMR challenge.

Dr Marlieke De Kraker (University of Geneva)